IOncology

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research and patient care.

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation." The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.

The 2026 CACA Cancer Prevention and Screening Conference recently opened in Hangzhou, bringing together leading oncologists, researchers, and industry experts from across China to discuss advances in cancer prevention, early detection, multidisciplinary collaboration, and translational research. Hosted by the Chinese Anti-Cancer Association (CACA) and its Cancer Prevention and Screening Committee, the meeting aligns with the goals of the Healthy China 2030 initiative by promoting earlier intervention throughout the cancer care continuum.

The Samsung Club National Young Breast Cancer Experts Conference recently concluded in Zhengzhou, bringing together emerging leaders from China's four major breast cancer academic organizations to discuss precision oncology, talent development, and multidisciplinary collaboration.

The Samsung Club National Young Breast Cancer Experts Conference recently concluded in Zhengzhou, bringing together rising leaders from China's four major breast cancer academic organizations to exchange ideas on precision oncology, physician training, and multidisciplinary collaboration.

"White clouds drift above the Chilechuan Plain, while the songs of Qingcheng echo like poetry." Against this vibrant midsummer backdrop, the 2026 Chinese Clinical Oncology Annual Advances Conference (BOC) & Best of CSCO 2026 China will be held in Hohhot, Inner Mongolia, from July 3–4, 2026.

As survival continues to improve for patients with breast cancer, postoperative quality of life (QoL) has become an increasingly important factor in surgical decision-making. Breast reconstruction is an integral component of comprehensive breast cancer care, and the choice of reconstructive technique has a profound impact on long-term functional recovery and psychosocial well-being.

At the 2026 ASCO Annual Meeting, the SENOMAC trial presented its final 5-year overall survival (OS) results together with patient-reported arm morbidity outcomes. The findings further confirmed that, among patients with one or two sentinel lymph nodes containing macrometastases, omission of completion axillary lymph node dissection (ALND) is not only oncologically non-inferior but also significantly improves upper-limb function and lymphedema-related quality of life.

In the era of chemotherapy alone, patients with high-risk early-stage triple-negative breast cancer (TNBC)—particularly those with node-positive disease or more advanced tumors—continued to face a substantial risk of recurrence after surgery, making cure an ambitious goal for many. Over the past few years, however, immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have rapidly moved from the metastatic setting into early-stage treatment, bringing new hope for long-term survival and potential cure.